Dihydropyrimidine dehydrogenase (dihydrouracil
dehydrogenase, dihydrothymine dehydrogenase, uracil reductase, EC
220.127.116.11, DPD) is the initial rate-limiting enzyme in pyrimidine
catabolism. DPD is important in the catabolism of not only the
naturally occurring pyrimidines uracil and thymine, but also the
widely used antimetabolite cancer chemotherapy agent 5-fluorouracil
(5-FU).[1,2] DPD thus occupies an important position in the overall
metabolism of 5-FU, converting over 85% of clinically administered
5-FU to 5-FUH2, an inactive metabolite, in an enzymatic
step that is effectively irreversible (Figure
1). While anabolism is clearly critical in the conversion of
5-FU to the active nucleotides FdUMP, FUTP, and FdUTP (these
metabolites can in turn inhibit cell replication through inhibition
of thymidylate synthase, or through incorporation into RNA or DNA,
respectively), catabolism controls the amount of 5-FU available for
anabolism and thus occupies a critical position in the overall
metabolism of 5-FU.
Because of the widespread use of fluoropyrimidines in oncology, it is
particularly desirable to be able to assess DPD activity in the
clinical setting. The ability to measure DPD in human tissue has
further increased our appreciation of the importance of DPD for 5-FU
pharmacology (see below).
Currently there are three different methods used to measure DPD
activity. Two of the methods are direct assays of DPD activity; one
being an HPLC-radioassay for DPD activity and the second being an
immunoblot assay of DPD protein. A third method, useful mainly in
the in vivo or clinical setting, is an indirect assessment of DPD
activity. By quantitating the levels of uracil, the natural substrate
for DPD that increases when DPD is inhibited, an estimate of
remaining DPD activity can be made.
For most clinical studies of DPD activity, peripheral blood
mononuclear cells, isolated from heparinized blood on Ficoll-hypaque,
can be used to monitor for DPD activity. Following preparation of
cytosol, DPD activity can be assayed as follows: At a specific
protein concentration of cytosol, incubation is carried out at
37°C in the presence of reduced nicotinamide-adenine
dinucleotide phosphate (NADPH) and radiolabeled 5-FU. Samples can
then be removed at specified times (over 30 min) and analyzed by
reversed phase HPLC using a radiodetector. DPD activity is then
expressed as nmol of 5-FUH2 formed per min per mg of protein. This is
described more fully elsewhere.
The importance of DPD to the clinical pharmacology of 5-FU has been
shown in several recent studies that demonstrate how DPD can
influence the pharmacokinetics, bioavailability, toxicity, and
antitumor effectiveness of 5-FU.
DPD is known to have a circadian pattern in both animals and
humans.[6-8] Studies in patients given 5-FU infusion by automated
pumps have demonstrated that the circadian variation of tissue DPD
level is accompanied by an inverse circadian pattern in plasma 5-FU
concentrations. This has potential importance in the design of
time-modified 5-FU infusions. Such regimens have been suggested to
have potential benefit in the treatment of certain human cancers.
DPD enzyme activity in normal tissues (peripheral blood mononuclear
cells and liver) has also been shown to vary among individuals in a
Gaussian pattern, with as much as a sixfold variation from the lowest
to the highest values.[10,11] This wide variation in DPD activity is
likely responsible for the wide variation in the t½b observed in
patients in population studies.
In addition to the variation of DPD activity observed in the normal
population, it is now clear that an additional small percentage (<
5%) of the population has DPD activity significantly below the
Gaussian distribution that characterizes most of the
population.[13-15] These individuals are at significant risk if they
develop cancer and are given 5-FU. This is a true pharmacogenetic
syndrome with symptoms that are not recognized until patients are
exposed to the drug.
Recently, variation in DPD activity has also been shown to be
responsible for variable bioavailability observed following oral
administration of 5-FU. The erratic bioavailability of 5-FU had not
previously been understood, particularly because 5-FU is a relatively
small molecule with a pKa that would predict excellent absorption and
bioavailability. Experimental studies using DPD inhibitors have
demonstrated in rodents that following inhibition of DPD the
pharmacokinetic pattern resulting from oral administration of 5-FU is
essentially the same as that produced by intravenous administration,
suggesting almost 100% bioavailability.
Tumors may also express a variable level of DPD activity. This
potentially may explain the observed varied tumor response to
5-FU. Tumors with relatively low levels of DPD should predict
sensitivity to 5-FU, while tumors with relatively high levels of DPD
should predict resistance to 5-FU.
The studies described above detailing the variability in DPD levels
in both normal and tumor tissues provide an explanation for the
observed variability in 5-FU pharmacology and at the same time
suggest a potential target for chemotherapy. It thus becomes
attractive for the oncologist to consider inhibiting DPD in order to
eradicate the variability in 5-FU pharmacology. Inhibiting DPD in 5-FU-susceptible
host tissue, such as GI mucosa and bone marrow, should make dosing
from patient to patient less variable. Inhibition of DPD in tumor
specimens is also attractive because it is likely that many tumors
achieve resistance to 5-FU through an increase in DPD activity within
the tumor resulting in increased degradation and thus less
opportunity for anabolism of 5-FU.
Over the years there have been many attempts to synthesize effective
inhibitors of DPD. Unfortunately, many of these compounds have
proven to be very toxic. In the past several years, new
fluoropyrimidine drugs introduced into the clinic have shown that
pharmacologic modulation of DPD can result in antitumor efficacy with
Four new fluoropyrimidine drugs using DPD modulators are currently
being evaluated in clinical studies. These include UFT, eniluracil,
S-1, and BOF-A2. These drugs differ in the type of DPD modulation as
well as the relative degree of inhibition of DPD produced. All of
these drugs achieve therapeutic gains from DPD modulation. Most
impressive is the fact that DPD modulation permits oral
administration of these drugs and results in less pharmacokinetic variability.
UFT was the first of these drugs to be synthesized (more than 20
years ago) and is the one for which we have the most clinical
experience. This novel fluoropyrimidine is a combination of the
naturally occurring pyrimidine uracil with the fluoropyrimidine
tegafur (ftorafur) in a 4:1 molar ratio. The presence of uracil in
excess of 5-FU results in competition at the level of DPD such that
5-FU formed from tegafur will not be rapidly degraded and will remain
present for a prolonged period (Figure
2). While not actual inhibition of DPD, the competition at the
DPD level produces an effect similar to that accomplished with a true
DPD inhibitor. In contrast to true DPD inhibitors and inactivators,
the effect on DPD is more rapidly reversible. There are now extensive
data from Japan as well as Europe, South America, and the United
States demonstrating that oral UFT administered either as a single
agent or combined with leucovorin has antitumor activity in several
tumor types (particularly breast and colon cancer) that is at least
as good as that achieved with IV 5-FU. Furthermore, the toxicity
profile has been shown to be tolerable, with the typical
fluoropyrimidine toxicities (eg, diarrhea and nausea) seen at the
maximal tolerated dose (MTD). Of note is the virtual absence of other
toxicities, in particular hand-foot syndrome, neurologic toxicity,
and cardiotoxicity. Although not well understood, these
toxicities have been thought to be possibly secondary to the
formation of 5-FU catabolites. Because of modulation at the DPD
level, 5-FU catabolites are less likely to form from UFT.
In Japan, there have been several attempts to develop this drug
combination concept further. S-1 is a triple drug combination (Figure
3) consisting of the prodrug tegafur (same as in UFT) together
with a true DPD inhibitor 5-chloro-2,4-dihydroxypyridine (CDHP) and
potassium oxonate in a molar ratio of 1:0.4:1, respectively. S-1
permits sustained 5-FU release from the 5-FU prodrug, with DPD
modulation in this combination being more potent secondary to the
effect of an actual DPD inhibitor. The third drug in this
combination, potassium oxonate, was added theoretically to lessen the
potential for typical 5-FU gastrointestinal toxicity (particularly
diarrhea) seen with most fluoropyrimidine drugs. In preclinical
studies, potassium oxonate was shown to selectively inhibit 5-FU
phosphorylation by the enzyme orotate phosphoribosyltransferase,
particularly in the gastrointestinal tract but not in tumors.
Results of preclinical studies have been encouraging, demonstrating
excellent antitumor activity. In clinical studies thus far, S-1
has been quite tolerable.[27,28]
BOF-A2 represents another attempt to develop an improved
fluoropyrimidine drug. With this two-drug combination, the prodrug
1-ethoxymethyl 5-fluorouracil (EM-FU) is combined with the DPD
inhibitor 3-cyano-2,6-dihydroxypyridine (CNDP) in a 1:1 molar
ratio. EM-FU is relatively resistant to degradation and is
metabolized to 5-FU by the liver microsomes. Preclinical studies have
confirmed the antitumor activity of BOF-A2 in several animal models
and have also demonstrated sustained 5-FU levels resulting from
release of 5-FU from EM-FU. Clinical studies have been conducted in
Japan, and more recently, limited studies have begun in the United
States. It is too early to comment on the possible clinical
effectiveness of this drug combination because of the limited patient
data available. In US studies of BOF-A2 thus far, however, typical
5-FU toxicities were observed, with some patients experiencing more
severe toxicity. At present, the dose, schedule, and potential
for combining this agent with other modulators (eg, leucovorin) are
Recently, eniluracil (ethynyluracil or GW776C85), an even more potent
inhibitor of DPD, has been synthesized. This agent has been
demonstrated to be a potent inactivator of DPD.
Eniluracil is a pyrimidine with a structure similar to that of both
uracil and 5-FU (Figure 4) that
has been shown to rapidly and completely inactivate DPD (Figure
5). Animals exposed over prolonged periods to relatively low
doses of eniluracil alone had no obvious toxicity. Following the
inhibition of DPD in these animals, a concomitant increase in plasma
uracil has been observed. Identification of an effective,
nontoxic dose of eniluracil has permitted evaluation of this drug
combined with various low doses of 5-FU. Results of pharmacokinetic
studies in rodents demonstrated remarkably reproducible 5-FU
pharmacokinetics. Subsequent rodent studies showed that 5-FU
could be administered orally in reproducible intra-animal and
interanimal studies, with bioavailability being demonstrated to be
The effectiveness of 5-FU and eniluracil in inhibiting tumor growth
has been demonstrated in several animal models, with evidence of
complete tumor regression in models in which only modest antitumor
effect had previously been seen.
Initial phase I clinical studies with eniluracil examined
administration of the drug alone orally for 7 days at doses of 0.74,
3.7, or 18.5 mg/m² to determine both the initial clinical
pharmacologic characteristics and the toxicity profile.
Pharmacokinetic evaluation demonstrated a t½ of 4.5 hours for
each of these doses. No changes were noted in the pharmacokinetics of
eniluracil with repeated doses compared with single doses.
Of particular interest is the effect of these doses of eniluracil on
DPD activity in the clinical setting. To assess DPD activity,
peripheral blood mononuclear cells were examined using the
methodology described above. Results demonstrated that DPD was
rapidly and completely inactivated by eniluracil, and inhibition was
maintained for more than 1 day at clinically used doses (Figure
6). Currently, phase II studies are ongoing or planned to
evaluate the effectiveness of the coadministration of 5-FU and
eniluracil in several different malignancies.
Improved efficacy of chemotherapy may result from eliminating 5-FU
degradation by tumor DPD, making DPD inactivation appealing as a
therapeutic goal. Studies are under way to evaluate whether
eniluracil can produce this effect in clinical studies. One
concern, however, is the length of time DPD remains inhibited in
normal host tissues, and clinical studies are currently planned to
evaluate this potential toxicity.
In summary, DPD activity is a critical step in pyrimidine metabolism
and is responsible for much of the variability in pharmacokinetics,
oral bioavailability, toxicity, and efficacy following administration
of 5-FU. Modulation of DPD activity through relative DPD inhibition
should result in less variation in 5-FU pharmacokinetics and
bioavailability and potentially may improve the drugs
therapeutic effectiveness both by making toxicity (after 5-FU dosing)
more predictable and by overcoming the high levels of DPD activity in
tumors where elevated DPD is a mechanism of tumor resistance. The
recent availability of DPD modulators such as UFT, S-1, BOF-A2, and
eniluracil offer the potential to decrease the variability due to DPD
and produce an improved fluoropyrimidine therapeutic effect. The type
of DPD modulation and relative degree of inhibition of DPD varies
with each drug. These differences may in turn account for differences
in efficacy and toxicity. Further investigation, including
comparative studies, is needed to clarify these differences.
1. Daher GC, Harris BE, Diasio RB: Metabolism of pyrimidine analogues
and their nucleosides, in: Metabolism and Reactions of Anticancer
Drugs, Vol. 1, in Powis G (ed): The International Encyclopedia of
Pharmacology and Therapeutics, chapter 2, Oxford, Pergamon Press, 1994.
2. Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil.
Clin Pharmaco 16:215-237, 1989.
3. Lu Z-H, Zhang R, Diasio RB: Purification and characterization of
dihydropyrimidine dehydrogenase from human liver. J Biol Chem
4. Yan J, Tyring SK, McCray MM, et al: The effect of sorivudine on
dihydropyrimidine dehydrogenase activity in patients with acute
herpes zoster. Clin Pharmacol Ther 61:563-573, 1997.
5. Johnson MJ, Yan J, Albin N, et al: Rapid screening for
dihydropyrimidine dehydrogenase (DPD) deficiency, a condition
associated with 5-fluorouracil toxicity. J Chromatogr Biomed Appl 696:183-191,
6. Harris BE, Song R, He Y, et al: Circadian rhythm of rat liver
dihydropyrimidine dehydrogenase: Possible relevance to
fluoropyrimidine chemotherapy. Biochem Pharm 37:4759-4763, 1988.
7. Harris BE, Song R, Soong S-J, et al: Circadian variation of
5-fluorouracil catabolism in isolated perfused rat liver. Cancer Res
8. Harris BE, Song R, Soong S-J, et al: Relationship of
dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil
levels: Evidence for circadian variation of 5-fluorouracil levels in
cancer patients receiving protracted continuous infusion. Cancer Res
9. Zhang R, Diasio RB: Pharmacologic basis for circadian
pharmacodynamics, in: Hrushesky WJM (ed): The Scientific Basis for
Optimized Cancer Therapy. Chapter 4, Boca Raton, CRC Press, 1994.
10. Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase
activity in human peripheral blood mononuclear cells and liver:
population characteristics, newly identified patients, and clinical
implication in 5-fluorouracil chemotherapy. Cancer Res 53:5433-5438, 1993.
11. Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase
activity in human liver: Population characteristics and clinical
implication in 5-FU chemotherapy. Clin Pharmacol Ther 58: 512-522, 1995.
12. Heggie GD, Sommadossi JP, Cross DS, et al: Clinical
pharmacokinetics of 5-fluorouracil and its metabolites in plasma,
urine, and bile. Cancer Res 47:2203-2206, 1987.
13. Diasio RB, Beavers TL, Carpenter JT: Familial deficiency of
dihydropyrimidine dehydrogenase: Biochemical basis for familial
pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin
Invest 81:47-51, 1988.
14. Harris BE, Carpenter JT, Diasio RB: Severe 5-fluorouracil
toxicity secondary to dihydropyrimidine dehydrogenase deficiency: A
potentially more common pharmacogenetic syndrome. Cancer 68:499-501, 1991.
15. Takimoto CH, Lu Z-H, Zhang R, et al: Severe neurotoxicity
following 5-fluorouracil-based chemotherapy in a patient with
dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res
16. Lu Z, Diasio RB: Polymorphic drug metabolizing enzymes, in:
Schilsky RL, Milano GA, Ratain MJ (eds): Principles of Antineoplastic
Drug Development and Pharmacology. New York, Marcel Dekker, Inc, 1996.
17. Baccanari DP, Davis ST, Knick VC, et al: 5-ethynyluracil: Effects
on the pharmacokinetics and antitumor activity of 5-fluorouracil. Pro
Natl Acad Sci 90:11064-11068, 1993.
18. Jiang W, Lu Z, He Y, et al: Dihydropyrimidine dehydrogenase
activity in hepatocellular carcinoma; implication for
5-fluorouracil-based chemotherapy. Clin Cancer Res 3:395-399, 1997.
19. Danenberg K, Salonga D, Park JM, et al: Dihydropyrimidine
dehydrogenase and thymidylate synthase gene expressions identify a
high percentage of colorectal tumors responding to 5-fluorouracil.
Proc Am Soc Clin Oncol 17:258a, 1998.
20. Naguib FNM, el Kouni MH, Cha S: Enzymes of uracil catabolism in
normal and neoplastic human tissues. Cancer Res 45:5405-5412, 1985.
21. Fujii S, Kitano S, Ikenaka K, et al: Studies on coadministration
of uracil or cytosine on antitumor activity of FT-207 or 5-FU
derivatives. Gan to Kagaku Ryoho 6:377-384, 1979.
22. Taguchi T: Experience with UFT in Japan. Oncology 11(10):30-34, 1997.
23. Pazdur R: Phase I and pharmacokinetic evaluations of UFT plus
oral leucovorin. Oncology 11:35-39, 1997.
24. Shirasaka T, Shimamato Y, Ohsimo H, et al: Development of a novel
form of oral 5-fluorouracil derivative (S-1) directed to the
potentiation of the tumor selective cytotoxicity of 5-fluorouracil by
two biochemical modulators. Anticancer Drugs 7:548-557, 1996.
25. Shirasaka T, Shimamato Y, Fukushima M: Inhibition by oxonic acid
of gastrointestinal toxicity of 5-fluorouracil without loss of its
antitumor activity in rats. Cancer Res 53:4004-4009, 1993.
26. Shirasaka T, Nakano K, Takechi T, et al: Antitumor activity of 1M
Tegafur-0.4 M 5-Chioro-2, 4-dihydroxypyridine-1 M potassium oxonate
(S-1) against human colon carcinoma orthotopically implanted into
nude rats. Cancer Res 56:2602-2606, 1996.
27. Ohtsu A, Sakata Y, Horioshi N, et al: A phase II study of S-1 in
patients with advanced gastric cancer. Proc Am Soc Clin Oncol
28. Baba H, Ohtsu A, SakataY, et al: Late phase II study of S-1 in
patients with advanced colorectal cancer in Japan. Proc Am Soc Clin
Oncol 17:277a, 1998.
29. Shirasaka T, Fujita F, Fujita M, et al: Antitumor activity and
metabolism of BOF-A2, a new 5-fluorouracil-derivative with human
cancers xenografted in nude mice. Gan to Kagaku Ryoho 17:1871-1876, 1990.
30. Sasaki T: New anti-cancer drugs for gastrointestinal cancers. Gan
To Kagaku Ryoho 24:1925-1931, 1997.
31. Spector T, Harrington JA, Porter DJT: 5-Ethynyluracil:
Inactivation of dihydropyrimidine dehydrogenase in vivo. Biochem
Pharmacol 46:2243-2248, 1993.
32. Cao S, Rustum YM, Spector T: 5-Ethynyluracil (776C85): Modulation
of 5-fluorouracil efficacy and therapeutic index in rats bearing
advanced colorectal cancer. Cancer Res 54:1507-1510, 1994.
33. Spector T, Porter DJT, Nelson DJ, et al: 5-Ethynyluracil
(776C85), a modulator of the therapeutic activity of 5-fluorouracil.
Drugs of the Future 19:566-571, 1994.
34. Paff MT, De Le Mata MA, Nelson DJ: Pharmacokinetics and
metabolism of 5-ethynyluracil, an inhibitor of 5-fluorouracil in
catabolism of CD-1 mice. Proc Am Assoc Can Res 35:321, 1994.
35. Baker SD, Khor SP, Adjei AA, et al: Pharmacokinetics, oral
bioavailability, and safety study of fluorouracil in patients treated
with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J
Clin Oncol 14:3085-3096, 1996.
36. Schilsky RL, Burris H, Ratain M, et al: Phase I clinical and
pharmacologic study of 776C85 plus 5-fluorouracil in patients with
advanced cancer. J Clin Oncol 16: 1450-1457, 1998.
37. Diasio RB: Improving 5-FU with a novel dihydropyrimidine
dehydrogenase inactivator. Oncology 12 (3; suppl 4): 51-56, 1998.